![]() The large share of this segment can be attributed high sensitivity and specificity, long elevation times, and rapid prediction of outcome or mortality. Troponin I and T is estimated to be the fastest-growing segment in the cardiac marker testing market. Troponin I and T estimated to be the fastest-growing market Growing number of cardiac marker testing procedures, accessibility to a wide range of cardiac biomarker reagents and kits, and the growing demand for reliable, specific, and faster detection of cardiovascular diseases at an early stage are the key growth factors for this segment. Wide use of reagents and kits in all basic diagnostic activities in laboratories, academic institutes, and POC settings is expected to result in the segment occupying the majority of the cardiac marker testing market share All areas of cardiology service provision sustained significant reductions, which included outpatient clinics, investigations, procedures, and cardiology community services such as cardiac rehabilitation. ![]() The cardiac marker testing market is also faced a period of short-term negative growth, which can be attributed to factors such as a greater than 50% drop in the number of patients with cardiovascular conditions and those diagnosed with myocardial infarction. ![]() COVID-19 has impacted their businesses as well. These suppliers have their manufacturing facilities spread across regions such as North America and Europe. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), and Danaher Corporation (US). The cardiac marker testing market includes major Tier I and II suppliers like Roche Diagnostics Ltd. However, factors such as technical problems related to sample collection and storage and issues related to regulatory and reimbursement systems are expected to restrain market growth to a certain extent. The growing incidence of cardiovascular diseases, rapidly increasing geriatric population, growing funding from public and private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers. According to the new market research report " Cardiac Marker Testing Market by Product (Reagent, Instrument), Component (Troponin I & T, CK-MB, Myoglobin, BNP, hsCRP), Disease (Myocardial Infarction, Congestive Heart Failure, Atheresclerosis), Enduser (Lab, PoC, Academia) - Global Forecasts to 2025", published by MarketsandMarkets™, the market is estimated to be USD 3.6 billion in 2020 and projected to reach USD 5.5 billion by 2025, at a CAGR of 8.9%.īrowse in-depth TOC on "Cardiac Marker Testing Market"ĭownload PDF Brochure: - Cardiac Marker Testing Market
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |